

Technical Update

April 6, 2026

New Test Notification

MiraVista Diagnostics now offers MycoMEIA® Aspergillus Galf Urine EIA, a urine-based antigen assay that complements serum galactomannan (GM) testing and may improve diagnostic confidence for invasive aspergillosis (IA).

Clinical Utility:

- Enhances diagnostic confidence for IA when used alongside serum GM testing.
- Provides complementary, noninvasive urine-based detection - useful when serum results are negative or evolving, particularly early in disease.
- Addresses variable serum GM sensitivity (~61–79%) across disease stages and patient populations.
- Supports antifungal stewardship by improving rule-out confidence and guiding targeted therapy.
- Applicable to transplant, oncology, and ICU populations.
- Designed to complement, not replace, serum GM testing within diagnostic algorithms.

MycoMEIA® should be used alongside clinical findings, imaging, and other laboratory results to support the diagnosis of invasive aspergillosis.